Key Details
Annual ROE
575.45%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 12, 2023Recent annual earnings:
Mar 16, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 13, 2022Analyst ratings
Recent major analysts updates
21 Dec '22 HC Wainwright & Co.
Buy22 Sept '21 Cantor Fitzgerald
Overweight18 May '20 Wells Fargo
Overweight15 May '20 H.C. Wainwright
Buy01 Apr '20 B. Riley FBR
Neutral28 Feb '20 B. Riley FBR
Buy28 Jan '20 BTIG
Buy21 Jan '20 Wells Fargo
Overweight29 May '19 B. Riley FBR
Buy25 Mar '19 H.C. Wainwright
BuyScreeners with IMV included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
IMV doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of IMV?
- What is the ticker symbol for IMV?
- Does IMV pay dividends?
- What sector is IMV in?
- What industry is IMV in?
- What country is IMV based in?
- When did IMV go public?
- Is IMV in the S&P 500?
- Is IMV in the NASDAQ 100?
- Is IMV in the Dow Jones?
- When was IMV's last earnings report?
- When does IMV report earnings?
- Should I buy IMV stock now?
What is the primary business of IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
What is the ticker symbol for IMV?
The ticker symbol for IMV is NASDAQ:IMV
Does IMV pay dividends?
No, IMV does not pay dividends
What sector is IMV in?
IMV is in the Healthcare sector
What industry is IMV in?
IMV is in the Biotechnology industry
What country is IMV based in?
IMV is headquartered in Canada
When did IMV go public?
IMV's initial public offering (IPO) was on 24 October 2007
Is IMV in the S&P 500?
No, IMV is not included in the S&P 500 index
Is IMV in the NASDAQ 100?
No, IMV is not included in the NASDAQ 100 index
Is IMV in the Dow Jones?
No, IMV is not included in the Dow Jones index
When was IMV's last earnings report?
IMV's most recent earnings report was on 12 May 2023
When does IMV report earnings?
The date for IMV's next earnings report has not been announced yet
Should I buy IMV stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions